2022 Revenues ($USD) : $1,233,286,650
2022 Revenues (foreign currencies) : AU$1,641,100,000
2022 R&D spend : $158,341,050
2022 Number of Employees : n/a
Fiscal Year End : 6/30/2022
Company CEO : Dig Howitt, president and CEO

Cochlear was founded in Sydney, Australia, in 1981. The company develops ear implants to help people with hearing loss. Cochlear offers the Nucleus cochlear implant, the Hybrid electro-acoustic implant and the Baha bone conduction implant. In January, the company received FDA approval for extended applications of its Nucleus implants. The implants treat unilateral hearing loss (UHL) and single-sided deafness (SSD). The implants were already FDA approved for those with moderate to profound bilateral sensorineural hearing loss. –SW